AA
TERN

ALPS Advisors’s Terns Pharmaceuticals TERN Stock Holding History

ALPS Advisors’s Portfolio TERN Stock Details TERN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-42,630
Closed -$320K – 1082
2025
Q3 		$320K Sell
42,630
-4,526
-10% -$28.9K ﹤0.01% 948
2025
Q2 		$176K Buy
+47,156
New +$147K ﹤0.01% 1012
2023
Q4 		– Sell
-45,028
Closed -$226K – 1012
2023
Q3 		$226K Buy
45,028
+3,363
+8% +$21.3K ﹤0.01% 948
2023
Q2 		$365K Buy
41,665
+10,062
+32% +$117K ﹤0.01% 695
2023
Q1 		$374K Buy
31,603
+6,078
+24% +$58.1K ﹤0.01% 653
2022
Q4 		$260K Buy
+25,525
New +$170K ﹤0.01% 945

Other funds holding TERN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CLGM
Capitolis Liquid Global Markets New York $15.7B AUM 30.78% 1-Year Est. Return

ALPS Advisors's TERN Position: Q4 2025 in Review

ALPS Advisors sold out of Terns Pharmaceuticals (TERN) in Q4 2025, closing a stake of 42,630 shares — an estimated $320K sold.

ALPS Advisors first reported a position in TERN in Q4 2022 and held it in 6 quarters. The position peaked at $374K in Q1 2023. 248 funds tracked by Wall St. Rank hold TERN as of Q4 2025.

  • ALPS Advisors reported no remaining Terns Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
  • ALPS Advisors sold 42,630 Terns Pharmaceuticals shares in Q4 2025, an estimated $320K.
  • ALPS Advisors first reported a position in Terns Pharmaceuticals in Q4 2022 and held it in 6 quarters.
  • ALPS Advisors's Terns Pharmaceuticals position peaked at $374K in Q1 2023.
  • 248 funds tracked by Wall St. Rank held Terns Pharmaceuticals as of Q4 2025.

Based on ALPS Advisors's 13F filing for Q4 2025, filed 12 Feb 2026.